Nedocromil - Misplaced Pages

(Redirected from Nedocromil sodium) Chemical compound Pharmaceutical compound

Nedocromil
Clinical data


Trade names	Alocril
AHFS/Drugs.com	Monograph
MedlinePlus	a601243
Routes of administration	Inhalation and eye drops
ATC code	R01AC07 (WHO) R03BC03 (WHO), S01GX04 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Protein binding	89%
Metabolism	not metabolized
Elimination half-life	~3.3 hours
Excretion	excreted unchanged
Identifiers
IUPAC name 9-ethyl-4,6-dioxo-10-propyl-6,9-dihydro-4H-pyranoquinoline-2,8-dicarboxylic acid
CAS Number	69049-73-6
PubChem CID	50294
IUPHAR/BPS	7607
DrugBank	DB00716
ChemSpider	45608
UNII	0B535E0BN0
KEGG	D05129
ChEBI	CHEBI:7492
ChEMBL	ChEMBL746
CompTox Dashboard (EPA)	DTXSID7023356
ECHA InfoCard	100.233.208
Chemical and physical data
Formula	C₁₉H₁₇NO₇
Molar mass	371.345 g·mol
3D model (JSmol)	Interactive image
SMILES O=C\1c3c(N(/C(C(=O)O)=C/1)CC)c(c2O/C(=C\C(=O)c2c3)C(=O)O)CCC
InChI InChI=1S/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26) Key:RQTOOFIXOKYGAN-UHFFFAOYSA-N
(verify)

Nedocromil sodium is a medication considered as mast cell stabilizer which acts to prevent wheezing, shortness of breath, and other breathing problems caused by asthma. It is administered by an inhaler under the brand name Tilade, and as an eye drop under the brand name Alocril. The effects of nedocromil versus asthma are gradual rather than fast-acting and it is not indicated for acute respiratory distress compared to fast acting bronchodilators like albuterol or other well-known inhaler medications. Liquid preparations of nedocromil are available in the UK under the name Rapitil for use for allergic eye reactions. Nedocromil sodium has been shown to be effective in alleviating symptoms of allergic conjunctivitis.

Nedocromil is classified as a benzopyrone. Nedocromil acts as a mast cell stabilizer, inhibits the degranulation of mast cells, prevents release of histamine and tryptase, so preventing the synthesis of prostaglandins and leukotrienes. US Production of inhaled nedocromil ceased in April 2008 because it used CFCs as propellant.

References

Media related to Nedocromil at Wikimedia Commons

"ALOCRIL Product Information". Allergan. Archived from the original on 8 May 2013. Retrieved 17 May 2013.
Allen H. Dajani S (ed.). "ALOCRIL (nedocromil sodium) solution/ drops". DailyMed. U.S. National Institutes of Health. Retrieved 17 May 2013.
"Nedocromil eye drops". Patient.info. 2007-02-02. Retrieved 2009-08-04.
Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF). The Cochrane Database of Systematic Reviews. 2015 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMC 10616535. PMID 26028608.
"Questions and Answers:Phase-Out of CFC Metered-Dose Inhalers Containing flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil". U.S. Food and Drug Administration. 13 April 2010. Archived from the original on 2 February 2012.

Decongestants and other nasal preparations (R01)

Topical

Sympathomimetics, plain	Amidephrine Cyclopentamine Ephedrine Epinephrine Fenoxazoline Iproheptine Levmetamfetamine Methylephedrine Metizoline Naphazoline Oxymetazoline Phenylephrine Propylhexedrine Tetryzoline Tramazoline Tuaminoheptane Tymazoline Xylometazoline
Antiallergic agents, excluding corticosteroids	Spaglumic acid histamine antagonists (Levocabastine Antazoline Thonzylamine) mast cell stabilizer (some are also antihistamines) (Cromoglicic acid Nedocromil Azelastine Olopatadine Lodoxamide)
Corticosteroids	Beclometasone dipropionate Betamethasone Budesonide Ciclesonide Dexamethasone Flunisolide Fluticasone (Fluticasone furoate, Fluticasone propionate) Mometasone furoate Prednisolone Tixocortol Triamcinolone Triamcinolone acetonide
Other nasal preparations	Cafaminol Calcium hexamine thiocyanate Eucalyptus oil Framycetin Hexamidine Hyaluronan Ipratropium bromide Mupirocin Retinol Ritiometan Saline water
Combination products	Olopatadine/mometasone

Systemic use:
Sympathomimetics

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

Drugs for obstructive airway diseases: asthma/COPD (R03)

Adrenergics, inhalants

Short-acting β₂ agonists	Bitolterol Carbuterol Fenoterol Isoetarine Pirbuterol Procaterol Reproterol Rimiterol Salbutamol (albuterol)/Levosalbutamol (levalbuterol) Terbutaline Tulobuterol
Long-acting β₂ agonists	Bambuterol Clenbuterol Formoterol/Arformoterol Salmeterol
Ultra-long-acting β₂ agonists	Abediterol Carmoterol Indacaterol Olodaterol Vilanterol
Other	Clorprenaline Ephedrine (+theophylline, +theophylline/phenobarbital, theophylline/hydroxyzine) Epinephrine Etafedrine Hexoprenaline Isoprenaline (isoproterenol) Methylephedrine Orciprenaline (metaproterenol) Racephedrine

Glucocorticoids

Anticholinergics/
muscarinic antagonist

Mast cell stabilizers

Xanthines

Eicosanoid inhibition

Leukotriene antagonists	Montelukast Pranlukast Zafirlukast
Arachidonate 5-lipoxygenase inhibitors	Zileuton
Thromboxane receptor antagonists	Ramatroban Seratrodast
Non-xanthine PDE4 inhibitors	Ibudilast Roflumilast

Others/unknown

Combination products

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

Categories:

See also

References